Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
Heart Valves Unit, Georges Pompidou European Hospital, Université Paris Cité, INSERM, Paris, France.
EuroIntervention. 2023 Oct 23;19(8):634-651. doi: 10.4244/EIJ-D-23-00473.
Valvular heart disease (VHD) is one of the most frequent causes of heart failure (HF) and is associated with poor prognosis, particularly among patients with conservative management. The development and improvement of catheter-based VHD interventions have broadened the indications for transcatheter valve interventions from inoperable/high-risk patients to younger/lower-risk patients. Cardiogenic shock (CS) associated with severe VHD is a clinical condition with a very high risk of mortality for which surgical treatment is often deemed a prohibitive risk. Transcatheter valve interventions might be a promising alternative in this setting given that they are less invasive. However, supportive scientific evidence is scarce and often limited to small case series. Current guidelines on VHD do not contain specific recommendations on how to manage patients with both VHD and CS. The purpose of this clinical consensus statement, developed by a group of international experts invited by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee, is to perform a review of the available scientific evidence on the management of CS associated with left-sided VHD and to provide a rationale and practical approach for the application of transcatheter valve interventions in this specific clinical setting.
瓣膜性心脏病(VHD)是心力衰竭(HF)最常见的原因之一,与预后不良有关,特别是在保守治疗的患者中。基于导管的 VHD 介入技术的发展和改进拓宽了经导管瓣膜介入治疗的适应证,从不能手术/高危患者扩大到年轻/低危患者。与严重 VHD 相关的心源性休克(CS)是一种临床状况,死亡率极高,手术治疗通常被认为风险过高。鉴于经导管瓣膜介入治疗的创伤较小,它可能是一种很有前途的替代治疗方法。然而,支持性的科学证据很少,而且往往仅限于小病例系列。目前的 VHD 指南中没有关于如何治疗同时患有 VHD 和 CS 的患者的具体建议。本临床共识声明由欧洲经皮心血管介入协会(EAPCI)科学文件和倡议委员会邀请的一组国际专家制定,旨在对与左侧 VHD 相关的 CS 的管理的现有科学证据进行回顾,并为经导管瓣膜介入治疗在这一特定临床环境中的应用提供合理的依据和实用方法。